Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.
...
Published in Bulletin du Cancer
Background Survival of metastatic colon cancer (mCC) patients has considerably improved with optimization of new drugs regimen. Inactivation of TP53 pathway by TP53 mutations is observed in nearly half of colorectal tumors. The impact of such mutations has been poorly studied in the metastatic setting. Methods The files of 254 mCC treated in a...
